Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials is a research paper published in Journal of Cystic Fibrosis (2020). On theSindex it has a DataRank of 0.930. It has been cited 18 times, with 12 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.442
From this paper's citation signal
Citation Network Contribution
0.489
From 11 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 12 citers.
NIDDK NIH HHS
Grant: P30 DK089507
NHLBI NIH HHS
Grant: P01 HL128192
NCATS NIH HHS
Grant: UL1 TR002319
NCATS NIH HHS
Grant: UL1 TR002548
National Institutes of Health
Grant: 5P01HL128192-05
Personalized small molecule therapy for severe asthma and cystic fibrosis.
National Institutes of Health
Grant: 3UL1TR002548-03S1
Clinical and Translational Science Collaborative of Cleveland
National Institutes of Health
Grant: 3UL1TR002319-02S1
Transform Dissemination and Implementation Science in CTSA Programs
National Institutes of Health
Grant: 5P30DK089507-02
Translational Research Center for Expedite Novel Therapies in Cystic Fibrosis
Cystic Fibrosis Foundation
National Institutes of Health
FWCI
1.21
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals